Navigation Links
Experimental drug reduces brain damage, eliminates brain hemorrhaging in rodents afflicted by stroke
Date:10/25/2013

Center and The Scripps Research Institute, Zlokovic and his team gave tPA alone and in combination with 3K3A-APC to mature female mice and male hypertensive rats four hours after stroke. They also gave 3K3A-APC in regular intervals up to seven days after stroke. They measured the amount of brain damage, bleeding and motor ability of the rodents up to four weeks after stroke.

The researchers found that, under those conditions, tPA therapy alone caused bleeding in the brain and did not reduce brain damage or improve motor ability when compared to the control. The combination of tPA and 3K3A-APC, however, reduced brain damage by more than half, eliminated tPA-induced bleeding and significantly improved motor ability.

"Scientists all around the globe are studying potential stroke therapies, but very few have the robust preclinical data package that 3K3A-APC has," said Kent Pryor, Ph.D., M.B.A., ZZ Biotech's chief operating officer. "The results from Dr. Zlokovic's studies have been very promising."

Zlokovic's team previously reported similar results in young, healthy male rodents. A Phase 1 trial testing the safety of 3K3A-APC in healthy human volunteers, led by study co-author Patrick D. Lyden, M.D., of Cedars-Sinai, concluded in February.

"We now have opened an investigational new drug application at the FDA to conduct a Phase 2 clinical trial of 3K3A-APC in patients experiencing acute ischemic stroke," said Joe Romano, CEO and president of ZZ Biotech. "We are excited to see 3K3A-APC move from healthy volunteers to real patients suffering from this terrible disease."


'/>"/>

Contact: Alison Trinidad
alison.trinidad@usc.edu
323-442-3941
University of Southern California - Health Sciences
Source:Eurekalert

Page: 1 2

Related biology news :

1. Nicole George wins 2012 Journal of Experimental Biology Outstanding Paper Prize
2. Experimental drug combination selectively destroys lymphoma cells
3. Experimental gene therapy treatment for Duchenne muscular dystrophy offers hope for youngster
4. Bridges experimental and bioinformatics perspectives to delineate protein-DNA interactions
5. New findings on tree nuts and health presented at the Experimental Biology Meeting in Boston, Mass.
6. AMP joins the Federation of American Societies for Experimental Biology
7. Soy-based S-equol supplement reduces metabolic syndrome risk factors
8. Minimally invasive treatment for ruptured aneurysm: Safe, reduces mortality
9. Laparoscopy reduces the risk of small-bowel obstruction
10. Hot sauce ingredient reduces beer belly fat as a weight-loss surgery alternative
11. The absence of elephants and rhinoceroses reduces biodiversity in tropical forests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Calif. , July 30, 2015 ... services for gene function analysis and biomarker discovery, ... RNA (sgRNA) Knockout Library targeting all human protein ... and permanently "knock out" a gene,s function. Cellecta,s ... a high throughput screening tool so that researchers ...
(Date:7/23/2015)... Inc. (NASDAQ: AWRE ), a leading supplier of biometrics ... quarter ended June 30, 2015.  Revenue for ... of 33% compared to $6.8 million in the same quarter ... was $0.3 million, or $0.01 per diluted share, which compared ... same period a year ago.  Lower revenue ...
(Date:7/21/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology from ... also the user using unique personal identifiers including ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4
... cognitive impairment is a transitional stage between normal ... during this transformation have yet to be studied. ... of Technology, China constructed brain networks using resting-state ... populations (normal controls, patients with early mild cognitive ...
... drink changed how cells lining the nasal passages of hay ... did not lead to significant changes in hay fever symptoms, ... allergen exposure., Our immune system must distinguish between "friends" that ... have harmful effects. There is now a growing body ...
... is available in German . ... the establishment of nine new Collaborative Research Centres (CRCs). This was ... in Bonn. The new CRCs will receive a total of 64.4 ... months and a 20% programme allowance for indirect project costs . ...
Cached Biology News:Researchers have a nose for how probiotics could affect hay fever 2DFG establishes 9 new collaborative research centers 2DFG establishes 9 new collaborative research centers 3DFG establishes 9 new collaborative research centers 4DFG establishes 9 new collaborative research centers 5DFG establishes 9 new collaborative research centers 6
(Date:8/3/2015)... GERMANTOWN, Md. , Aug. 3, 2015   ... it will release first half and second quarter 2015 ... 10 th , 2015.  The Company will host a ... results and provide a general business update. ... (Domestic US) and 1-412-902-4262 (International), and asking to join ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... analysis and premium industry insights on the global resorcinol industry. The report highlights ... study of vivid market scenarios and analysis of primary and secondary inputs from ...
(Date:7/30/2015)... 2015   GenoSpace , a leading provider ... analysis of genomic and other biomedical data, today ... the company as Vice President of Sales and ... "GenoSpace partners with its customers ... and explore complex sets of genomic, phenotypic and ...
(Date:7/30/2015)... Kan. , July 30, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today announced that its strategic partner ... a dose confirmation study of AT-016, an adipose-derived ... for the treatment of osteoarthritis pain in dogs. ...
Breaking Biology Technology:Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5
...   Life Technologies Corporation (NASDAQ: LIFE ... Association Francaise de Normalisation (AFNOR) for its MicroSEQ® ... Listeria monocytogenes assays, molecular tests that are ... absence of this food-borne pathogen that most recently has ...
... that it has modified the provisions of its American Depository ... Limited ordinary shares for each ADR share will now be ... change will be effective from 3 January, 2012.  The change ... number of outstanding common shares the company has on issue ...
... (NASDAQ: HALO) will be presenting at the 30th Annual ... January 11, 2012 at 2:00 p.m. PT / 5:00 ... and chief executive officer of Halozyme Therapeutics, will provide ... The presentation will be webcast through the ...
Cached Biology Technology:Life Technologies Receives AFNOR Validation for Tests Designed to Detect Listeria Contamination in Food Samples 2Life Technologies Receives AFNOR Validation for Tests Designed to Detect Listeria Contamination in Food Samples 3Life Technologies Receives AFNOR Validation for Tests Designed to Detect Listeria Contamination in Food Samples 4
... Microarrays designed for genome-wide microRNA expression ... and powerful Paraflo microfluidic on-chip synthesis ... part of our comprehensive microRNA Expression ... The Fishes microRNA Microarray contains ...
...
... CP-4900 is a rugged, compact, ... the information you need - ... composition of gas mixtures is ... Chromatograph generates more data in ...
... an exciting new chapter to ... leadership, Agilents 7890A GC gives ... take your lab to the ... GC/MS performance, including advanced separation ...
Biology Products: